NervGen Pharma Corp. announced the appointment of Dr. Michael J. Abrams, PhD, to the Company’s Board of Directors. Dr. Abrams brings to NervGen extensive expertise and successes gained during his over thirty-year career in pharmaceutical discovery and development. He has considerable experience transforming scientific discovery into innovative and commercially successful products. Dr. Abrams is currently an Adjunct Professor of Chemistry at the University of British Columbia and is actively involved in the biotechnology community as an adviser and board member of numerous companies. He was the Founder, President & CEO of AnorMED Inc. which successfully developed Mozobil, a first-in class drug, approved for use in stem cell transplantation.